Modified GRF 1-29

What is Modified GRF 1-29?

A short-acting GHRH analog designed for pulsatile GH release without DAC extension; research-stage only.

This profile is educational. It organizes publicly discussed research context for Modified GRF 1-29 and related naming aliases — it is not a treatment guide.

Proposed mechanism

GHRH receptor agonism with D-amino acid modifications for stability while preserving short pulse kinetics.

Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.

Current research notes

Human evidence grade: Limited human evidence

Preclinical evidence grade: Early-stage human research

Mod GRF 1-29 is essentially CJC-1295 without DAC, intended to mimic natural pulsatile GH secretion when combined with GHRPs. Human PK data are more limited than DAC version. Not FDA approved. WADA prohibited.

Key uncertainties

• Advantage over other GHRH analogs clinically

Research areas being studied

• Pulsatile GH research
• Secretagogue combinations

Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.

Safety & side-effect notes

Reported or discussed adverse effects

• Injection-site reactions
• Flushing

Additional risks & considerations

• Unregulated products
• WADA prohibited
• Limited outcome trials

Regulatory status

Not FDA-approved

Regulatory framing here is educational and can lag policy changes. Check official sources for current status.

Frequently asked questions

References & sources

• Teichman SL et al. (2006). GHRH analog pharmacokinetics review — J Clin Endocrinol Metab. Evidence type: human.